If you made any changes in Pure these will be visible here soon.

Research Output 1990 2019


Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

Ascierto, P. A., Ferrucci, P. F., Fisher, R., Del Vecchio, M., Atkinson, V., Schmidt, H., Schachter, J., Queirolo, P., Long, G. V., Di Giacomo, A. M., Svane, I. M., Lotem, M., Bar-Sela, G., Couture, F., Mookerjee, B., Ghori, R., Ibrahim, N., Moreno, B. H. & Ribas, A., Jun 1 2019, In : Nature Medicine. 25, 6, p. 941-946 6 p.

Research output: Contribution to journalLetter

Blocking Antibodies
Mitogen-Activated Protein Kinase Kinases
3 Citations (Scopus)

CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab

Italian Melanoma Intergroup (IMI), Jul 1 2018, In : European Journal of Cancer. 97, p. 59-61 3 p.

Research output: Contribution to journalLetter